Artificial intelligence (AI) and deep learning models may help to predict the risk of cardiovascular disease events and detect heart valvular disease, according to two preliminary research studies.
News | Artificial Intelligence
AI May Accurately Detect Heart Valve Disease and Predict Cardiovascular Risk

November 6, 2023 — Advances in artificial intelligence have enabled the development and application of AI tools that may ...

Home November 06, 2023
Home
New clinical analyses and real-world data continue to demonstrate the benefit of treatment with CAMZYOS (mavacamten) for patients with symptomatic obstructive HCM
News | Cardiovascular Clinical Studies
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023

November 6, 2023 — Bristol Myers Squibb announced that research across the company’s cardiovascular franchise will be ...

Home November 06, 2023
Home
Study suggests CV risk factors and comorbidities could contribute to progression to dementia
News | Atrial Fibrillation
New Atrial Fibrillation Diagnosis May Increase risk of Memory Decline

November 6, 2023 — Atrial fibrillation (AF) diagnosis was associated with a 45% increased risk of mild cognitive ...

Home November 06, 2023
Home
Medical University of South Carolina researchers partner with Emergency Medical Services to pilot test the first MRI-equipped ambulance to speed stroke response
News | Stroke
An MRI-equipped Ambulance: A Game-changer for Stroke Care?

November 3, 2023 — In the U.S., someone has a stroke every 40 seconds and dies from it every three minutes and 14 ...

Home November 03, 2023
Home
Marlene Rabinovitch, MD, Stanford University
News | AHA
Dr. Marlene Rabinovitch to Receive the 2023 AHA Research Achievement Award

November 3, 2023 — The American Heart Association will present its 2023 Research Achievement Award to Marlene ...

Home November 03, 2023
Home
New Board of Cardiovascular Medicine will certify cardiovascular medicine physicians with more specific and more competency-based trainings and supports
News | Heart Failure
The American Heart Association Joins Consortium with Full Support for a New American Board of Cardiovascular Medicine

November 3, 2023 — The national Board of Directors of the American Heart Association last week voted to provide full ...

Home November 03, 2023
Home
DAIC VIVA23 Penumbra Flash Image
News | VIVA
Data from VIVA23 Late-breaking Clinical Trial Focuses on Computer-Assisted Vacuum Thrombectomy for Pulmonary Embolism

November 2, 2023 — The latest STRIKE-PE data, presented by Penumbra, Inc. at the Vascular Interventional Advances ...

Home November 02, 2023
Home
The University of Maryland Medical Center released a statement on the Oct. 30 passing of Lawrence Faucette, a 58-year-old patient with terminal heart disease who received the world’s second genetically-modified pig heart transplant Sept. 20 in a landmark cardiac xenotransplantation procedure.
News | Cardiovascular Surgery
UMMC Issues Statement on Passing of Man Who Received Second Pig Heart Transplant, Mourns Loss of Remarkable Patient, Scientist, Navy Veteran

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...

Home November 02, 2023
Home
Results of the PERFORMANCE II Trial were presented by William Gray, MD, System Chief, Division of Cardiovascular Diseases, Main Line Health, and Co-National Principal Investigator during the VIVA23 annual conference..
News | VIVA
PERFORMANCE II Carotid Stent Trial One-Year Outcomes Released at VIVA23

November 2, 2023 — Contego Medical Inc. announced the presentation of late-breaking clinical results from the ...

Home November 02, 2023
Home
DAIC VIVA23 Heart image
News | VIVA
VIVA23 Presents Outcomes of Late-breaking Science from Abbott’s LIFE-BTK, RESOLV FIH Study, and IN.PACT AV Access Trial

November 2, 2023 — The second round of late-breaking clinical trials results from the Vascular InterVentional Advances ...

Home November 01, 2023
Home
DAIC VIVA 23 logo
News | VIVA
Vascular InterVentional Advances Conference, VIVA23, Clinical Trial Outcomes: PROMISE II (LimFlow) Trial for TADV, PRELUDE Study (LimbSonic) Therapeutic Ultrasound Presented

November 1, 2023 — The VIVA Foundation has announced the results for the first Late-Breaking Clinical Trial sessions at ...

Home November 01, 2023
Home
DAIC The Veins 2023 logo
News | VIVA
Late-Breaking Clinical Trial outcomes from The VEINS Conference: CLOUT Registry, VIVID Trial, DEXTERITY-AFP Trial, and Venous Thromboembolism Treatment

October 31, 2023 — Results of four late-breaking clinical trials presented during the The VEINS Conference 2023, taking ...

Home October 31, 2023
Home
Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies
News | Structural Heart
CLASP IID One-year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized ...

Home October 31, 2023
Home
The findings will impact the interventional treatment of High Bleeding Risk patients
News | Stents Drug Eluting
Positive Results Revealed in Clinical Trial COMPARE 60/80 for High Bleeding Risk Patients

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
The findings will impact the interventional treatment of High Bleeding Risk patients
News | Ventricular Assist Devices (VAD)
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now